Previous close | 0.1570 |
Open | 0.1602 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.1602 - 0.1770 |
52-week range | 0.1500 - 1.0200 |
Volume | |
Avg. volume | 107 |
Market cap | 4.945M |
Beta (5Y monthly) | 0.11 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6950 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LAS VEGAS, NV, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Hestia Insight Inc. (OTCQB: HSTA) ("Hestia Insight" and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, and providing marketing, management, business, and capital markets advisory services to its clients within the healthcare and biotech sectors, today announced that through its wholly owned subsidiary, Hestia Investments Inc., the Company entered
LAS VEGAS, NV, Dec. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) ("Hestia Insight" and the “Company”), a company focused on the development and operation of novel technologies and providing marketing, management, business, and capital markets advisory services to its clients, today announced the launch of its new marketing plan - a strategic initiative designed to empower emerging growth companies by integrating professional expertise, top-tier talent, and AI
NEW YORK, NY, Aug. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, and providing marketing, management, business, and capital markets advisory services to its clients within the healthcare and biotech sectors, today announced that in September 2023, its wholly owned subsidiary, Hestia Investments Inc. (“Hestia Inve